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Summary
Killer immunoglobulin- like receptors (KIRs) regulate the activation of natural killer cells 
through their interaction with human leucocyte antigens (HLA). KIR and HLA loci are 
highly polymorphic, and certain HLA- KIR combinations have been found to protect 
against viral infections. In this study, we analysed whether the KIR/HLA repertoire 
may influence the course of hepatitis B virus (HBV) infection. Fifty- seven subjects 
with chronic hepatitis B (CHB), 44 subjects with resolved HBV infection and 60 healthy 
uninfected controls (HC) were genotyped for KIR and their HLA ligands. The frequency 
of the HLA- A- Bw4 ligand group was higher in CHB (58%) than subjects with resolved 
infection (23%) (crude OR, 4.67; P<.001) and HC (10%) (crude OR, 12.38; P<.001). 
Similar results were obtained for the HLA- C2 ligand group, more frequent in CHB 
(84%), than subjects with resolved infection (70%) (crude OR, 2.24; P<.10) and HC 
(60%) (crude OR, 3.56; P<.01). Conversely, the frequency of KIR2DL3 was lower in 
CHB (81%) than in subjects with resolved infection (98%) (crude OR, 0.10; P<.05). 
These results suggest a detrimental role of HLA- A- Bw4 and HLA- C2 groups, which are 
associated with the development of CHB, and a protective role of KIR2DL3. A step-
wise variable selection procedure, based on multiple logistic regression analysis, iden-
tified these three predictive variables as the most relevant, featuring high specificity 
(90.9%) and positive predictive value (87.5%) for the development of CHB. Our results 
suggest that a combination of KIR/HLA gene/alleles is able to predict the outcome of 
HBV infection.
K E Y W O R D S
hepatitis B virus, HLA, killer cell immunoglobulin-like receptor, natural killer
1  | INTRODUCTION
Viral hepatitis B affects millions of people worldwide. In the WHO 
European Region, an estimated 13.3 million adults (1.8% of 898.6 mil-
lion) have hepatitis B, and two- thirds of them are migrants or live in 
eastern Europe.1
Abbreviations: anti-HBc, anti-hepatitis B core total IgG antibodies; BIC, Bayesian information 
criterion; CHB, chronic hepatitis B; CMV, cytomegalovirus; HBV, hepatitis B virus; HCV, hep-
atitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; HLA, human leu-
kocyte antigens; KIRs, killer cell immunoglobulin-like receptors; NK, natural killer; PCR-SSP, 
polymerase chain reaction sequence-specific primer.
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A chronic course of hepatitis B virus (HBV) infection develops in 
less than 10% of immuno- competent adults with acute HBV infection, 
while the majority of patients resolve the infection.1 The reason for 
this different clinical picture is unknown.
Host immunity, both innate and adaptive, is a key determinant of 
the natural course of viral hepatitis B. Innate immunity is traditionally 
viewed as playing a critical role in the initial containment of viraemia 
in acute infections. The contribution of innate effectors, such as nat-
ural killer (NK) cells, is likely to be of particular relevance in the liver, 
where their frequencies are greatly enriched.2 However, whether NK 
cells are innocent bystanders or potent players, and the hierarchy of 
importance of these cells in the HBV- infected liver is still unknown.2
Killer cell immunoglobulin- like receptors (KIRs) on NK cells are 
involved in the control of virus infection by probing cells for proper 
expression on human leucocyte antigens (HLA) class I.3 Different 
KIRs can transmit inhibitory or activating signals to the cell, through 
the interaction with specific HLA ligands.4 Two broad haplotypes of 
KIR genes have been defined on the basis of gene content:5 the B 
haplotype is characterized by variable numbers of activating and in-
hibitory genes, whereas the A haplotype contains no functional acti-
vating KIR.5
Several epidemiological studies have associated KIR/HLA com-
pound genotypes with susceptibility to infectious diseases, such as 
human immunodeficiency virus (HIV),6,7 human cytomegalovirus 
(CMV)8-11 and hepatitis C virus (HCV).12 So far there are limited data 
on the relationship between KIR genes and their HLA ligands and the 
outcome of HBV infection,13-16 and no study has been performed on 
European populations. In this study, we investigated whether spe-
cific KIR or HLA gene variants influence the natural course of HBV 
infection.
2  | METHODS
2.1 | Patients
Fifty- seven Caucasoid Italian patients with chronic hepatitis B (CHB)17 
at any stage of liver disease with or without any antiviral treatment 
were recruited at the University of Palermo Medical Center in Palermo, 
Italy. As first control group, 44 candidate blood donors screened at 
the Transfusion Medicine Unit of the same hospital tested negative 
for anti- HIV I/II antibodies, antihepatitis C antibodies, HBsAg and for 
HIV, HCV and HBV nucleic acids (Tri- NAT assay; NAT, nucleic acid 
testing), but positive for antihepatitis B core total IgG antibodies (anti- 
HBc), with or without antibodies anti- HBsAg and/or anti- HBeAg were 
included (resolved infection). The analytical sensitivity of HBV DNA 
test (Tri- NAT assay) performed on individual plasma samples was 
10 copies/mL (Grifols International S.A., TMA, Ultrio Elite). As second 
control group, 60 blood donors (negative for anti- HIV I/II antibodies, 
antihepatitis C antibodies, HBsAg, anti- HBc antibodies and HIV/HCV/
HBV nucleic acids) already enrolled as healthy controls in a previous 
study were also included (Table 1).8 These subjects were all positive 
for IgG anti- CMV, as marker of a previous asymptomatic CMV infec-
tion.8 Informed consent was obtained for collection of samples from 
all patients and controls. Consent forms were administered by the 
physicians involved in the study.
2.2 | HLA and KIR genotyping
Peripheral whole blood samples were collected, and genomic DNA 
was extracted from leucocytes by a commercial kit (PureLink® 
Genomic DNA, ThermoFisher Scientific, Waltham, MA, USA). Using 
the polymerase chain reaction sequence- specific primer (PCR- SSP) 
technique, the DNA of cases and controls was genotyped for the 
presence of the three major KIR ligand groups: HLA- C1, HLA- C2 and 
HLA- Bw4, both HLA- B and HLA- A loci (Epitop- TYPE kit; BAG Health 
Care GmbH, Lich, Germany). KIR genotyping was performed for both 
inhibitory and activating KIR using the KIR- TYPE kit (BAG Health Care 
GmbH). KIR gene profiles were determined by the presence or ab-
sence of each KIR gene.
2.3 | Statistical analysis
Crude comparisons of gene frequencies were made using 2×2 con-
tingency tables, analysed by the chi- square test. A logistic regression 
model was also considered in analysing the data, to derive a reduced 
and easily interpretable model for predicting clinical outcomes. The 
procedure started from a full model, including a set of variables as co-
variates encompassing all KIR genes and their HLA ligands,4 except for 
those covariates having one unique value (zero- variance predictors) 
or covariates having very few unique values relative to the number 
of samples (details in Supporting Information). A stepwise procedure 
that compares nested models by Bayesian information criterion (BIC) 
was carried out to select the final subset of relevant predictors. By 
randomly splitting the data in two parts, a training set to select and 
estimate the final model and a test set to measure its performance, 
we were able to estimate its ability to predict the clinical course of 
the infection. We also conducted an internal validation of model pre-
dictive accuracy using a 10- fold cross- validation scheme (details in 
Supporting Information).18 The whole analysis was performed by R 
3.3.1 (R Core Team, 2013).19
3  | RESULTS
The characteristics of the study populations are reported in Table 1. 
The mean age of the 57 patients with CHB was 52.9±14 years (range 
22- 79 years), with a prevalence of males (66.6%). Thirteen of them 
were co- infected with HIV (22.8%), two with HCV (3.5%) and one with 
hepatitis D virus (HDV, 1.7%). The control population (44 subjects), 
represented by subjects with a previous asymptomatic HBV infection 
screened for blood donation (resolved infection), was similar for age 
(mean age, 52.7±8.5 years, range 37- 67 years) and sex (males, 66.6%). 
A second control group (60 subjects; 61.6% males), representing ac-
tive blood donors without any previous HBV infection, featured lower 
mean age (39.5 years).8 This second control population was added to 
assess whether there was a different KIR or HLA gene frequency in 
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the general population compared to infected subjects, both with re-
solved or persistent infection (CHB), considering that KIR and HLA loci 
are likely under pathogen- mediated selection.
To assess whether genetic variants of KIR and their HLA ligands 
may influence the outcome of the HBV infection, we first compared 
the frequencies of these gene families in subjects with CHB and sub-
jects with resolved infection (Table 2). The inhibitory KIR2DL3 gene 
was less frequent in CHB (81%) than in subjects with resolved in-
fection (98%) (crude OR, 0.10; P<.05). The only other KIR gene ex-
pressed differently between CHB and subject with resolved infection 
was the KIR2DS4- Del, which codes for an inactive receptor (crude 
OR, 4.36; P<.01). No difference was reported in the frequency of KIR 
haplotypes between the groups, suggesting that activating receptors 
likely do not play a role in the control of the infection (crude OR, 
1.23; P=.67).
Regarding the KIR ligand groups, the frequency of individuals with 
HLA- A- Bw4 alleles was higher in the group with CHB (58%) relative to 
the group that had resolved infection (23%) (crude OR, 4.67, P<.001). 
The frequency of HLA- B- Bw4 alleles did not differ significantly be-
tween the groups, while the frequency of HLA- C1 alleles was lower 
in the group with persistent infection (CHB, 65%) than with resolved 
infection (86%) (crude OR, 0.29; P<.05) (Table 2). Regarding the KIR- 
HLA ligand interactions, the frequency of the interaction between 
HLA- C1 and KIR2DL3 was lower in persistent infection (CHB, 53%) 
than in resolved infection (84%) (crude OR, 0.21, P<.001), while the 
interaction between HLA- C1 and KIR2DL2 did not differ between the 
groups. The frequency of the interaction between HLA- A- Bw4 and 
KIR3DL1 was the same as HLA- A- Bw4 as KIR3DL1 was expressed in 
almost all subjects (crude OR, 4.67, P<.001).
Stepwise logistic regression analysis supported the effect of 
HLA- A- Bw4 (Adj.- OR, 6.52, P<.05) and KIR2DL3 (Adj.- OR, 0.04, 
P<.01) (Table 3). Furthermore, the HLA- C2 alleles, which were more 
frequent in subjects with persistent infection (CHB, 84%) than in 
those with resolved infection (70%) with marginal statistical signif-
icance at the univariate analysis (crude OR, 2.24, P<.10) (Table 2), 
were significantly associated with the presence of persistent infec-
tion (Adj.- OR, 8.17, P<.05) (Table 3). Conversely, the effect of HLA- 
C1 was weakly significant (P<.10) in the multiple logistic regression 
analysis, and it was readily removed during the stepwise selection 
procedure, as well as KIR2DS4 genes (not significant). Similarly, sex 
and age analysed as conditioning variables did not show any sta-
tistically significant difference between the groups in the multiple 
variable logistic regression analysis, and they were removed during 
the stepwise selection phase as well. We also analysed the subpop-
ulations of HBV patients without HCV or HIV co- infections. The 
exclusion of patients with these co- infections led to similar results, 
confirming the validity of the conclusions (Supporting Information 
for details).
Stepwise selection of relevant genes was conducted on a training 
set, obtained by randomly splitting the whole data set in two parts: 
one part was used as training set and the other as test set (75/25 
split, 75% of data for training set, 25% for test set). The normalized 
effect sizes of each variable are reported in Table 4. The most re-
lated variables with the risk of developing CHB were ranked by the 
importance values from the highest (100%) to the smallest (0.00%) 
(Table 4). At variance with odds ratios (Table 3), such normalized ef-
fect sizes are expressed on a common scale of variation (0%- 100%), 
and they provide, for each gene, information about the relative im-
pact in explaining the probability that a randomly selected patient 
will develop CHB (Supporting Information for details). HLA- A- Bw4 
featured the highest relative impact on the outcome prediction 
(effect size: 100%), followed by KIR2DL3 (16.64%), and HLA- C2 
(0.00%). Using the test set, we were able to estimate the ability of 
the model to predict the clinical course. The balanced accuracy of 
the predictive model was fairly good (70.5%), with low sensitivity 
(50.0%), but high specificity (90.9%) and positive predictive value 
(87.5%) (Table 4). According to the predictive model, the presence 
of KIR2DL3 gene is highly protective (predicts resolved infection 
anytime it is present) if only one of the two detrimental HLA ligand 
groups (HLA- A- Bw4, HLA- C2) is present, but is unable to confer pro-
tection when both HLA- A- Bw4 and HLA- C2 are present (Table S1 in 
Supporting Information). In contrast, when KIR2DL3 is absent, only 
one of the two detrimental genes is able to predict the develop-
ment of persistent infection. A ten- fold cross- validation procedure 
was used to internally validate the predictive accuracy of the final 
model, producing an accurate and unbiased estimate of how well the 
Characteristic
CHB 
Ntot=57
Resolved infection 
Ntot=44
HC 
Ntot=60
Mean age, Y±SD 52.9±14.0 52.7±8.5 39.5±11.7
Y (range) (22- 79) (37- 67) (18- 65)
Sex, M (%) 38 (66.6) 30 (66.6) 37 (61.6)
Other infections, N (%)
HDV 1 (1.7) 0 0
HCV 2 (3.5) 0 0
HIV 13 (22.8) 0 0
CHB, chronic hepatitis B; resolved infection, subjects with resolved HBV infection; HC, healthy 
 controls: blood donors; HDV, hepatitis D virus; HCV, hepatitis C virus, HIV, human immunodeficiency 
virus; Ntot, total number of subjects; Y, years; M, males, SD, standard deviation.
TABLE  1 Clinical characteristics of the 
study populations
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Genetic factor
Frequency CHB 
Ntot=57 
N (%)
Frequency resolved infection 
Ntot=44 
N (%) Crude OR P- value
KIR haplotypes
AA 11 (19) 10 (23) – – 
AB+BB 46 (81) 34 (77) 1.23 .67
KIR alleles
2DL1 54 (95) 44 (100) N.A. N.A.
2DL2 34 (60) 23 (52) 1.35 .46
2DL3 46 (81) 43 (98) 0.10 <.05b
2DL4 57 (100) 44 (100) N.A. N.A.
2DL5A 27 (47) 23 (52) 0.82 .63
2DL5B 18 (32) 20 (45) 0.55 .16
2DS1 25 (44) 26 (59) 0.54 .13
2DS2 33 (58) 22 (50) 1.38 .43
2DS3 19 (33) 18 (41) 0.72 .43
2DS4 Full 4 (7) 8 (18) 0.34 <.10a
2DS4 Del 52 (91) 32 (73) 4.36 <.01c
2DS4 Del*008 0 (0) 1 (2) N.A. N.A.
2DS5 21 (37) 20 (45) 0.70 .38
3DL1 57 (100) 40 (91) N.A. N.A.
3DL2 57 (100) 44 (100) N.A. N.A.
3DL3 57 (100) 44 (100) N.A. N.A.
3DS1 26 (46) 23 (52) 0.77 .51
2DP1 53 (93) 44 (100) N.A. N.A.
3DP1 4 (7) 0 (0) N.A. N.A.
3DP1*003 53 (93) 44 (100) N.A. N.A.
HLA alleles
HLA- C1 37 (65) 38 (86) 0.29 <.05b
HLA- C2 48 (84) 31 (70) 2.24 <.10a
HLA- B- Bw4T 14 (25) 12 (27) 0.87 .76
HLA- B- Bw4I 32 (56) 29 (66) 0.66 .32
HLA- A- Bw4 33 (58) 10 (23) 4.67 <.001d
KIR- HLA combinations
2DL3/HLA- C1 30 (53) 37 (84) 0.21 <.001d
2DL2/HLA- C1 21 (37) 21 (48) 0.64 .27
2DS2/HLA- C1 20 (36) 20 (45) 0.65 .29
2DL1/HLA- C2 46 (81) 31 (70) 1.75 .23
2DS1/HLA- C2 23 (40) 20 (45) 0.81 .61
3DL1/HLA- B- Bw4I 32 (56) 26 (59) 0.89 .77
3DS1/HLA- B- Bw4I 12 (21) 14 (32) 0.57 .22
3DL1/HLA- B- Bw4T 14 (25) 12 (27) 0.87 .76
3DL1/HLA- A- Bw4 33 (58) 10 (23) 4.67 <.001d
The KIR- HLA interaction suggested by literature were analysed and reported in the table. Abbreviations: CHB, chronic hepatitis B; resolved infection, 
subjects with resolved HBV infection; HLA, human leucocyte antigen; KIR, killer immunoglobulin- like receptor; crude OR, unadjusted odds ratio derived 
from a 2×2 table. Statistically significant P- values have been expressed in relational terms with the statistical significance threshold, in the sense that “P<α” 
means that the null hypothesis of crude OR=1 can be rejected when the chosen significance threshold is equal to α. We report the following degree of evi-
dence against the null hypothesis: aweak statistical significance (P<.10); bmoderate statistical significance (P<.05); cstrong statistical significance (P<.01); 
dvery strong statistical significance (P<.001).
TABLE  2 Frequencies of KIR, HLA and KIR- HLA combinations among individuals with CHB and subjects with resolved infection
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proposed classifier correctly identifies or excludes CHB. The cross- 
validated accuracy was 70.0%, strongly confirming the goodness of 
our analysis (Table 4).
Considering that a high proportion of subjects who resolve the 
acute infection characterizes the natural history of HBV infection, 
we further assessed the frequency of KIR and their HLA ligands in 
the second control population represented by active blood donors 
without any previous HBV infection. This second control group (60 
subjects) that represents the general population was compared to in-
fected subjects, both with resolved or persistent infection (CHB). This 
group, referred as healthy controls (HC), was represented by subjects 
already enrolled in another study with a previous CMV asymptomatic 
infection, and featured lower mean age (39.5 years).8 The different 
age was considered not relevant for this analysis as the variable “age” 
was not shown to be associated with the outcome. The presence of 
a previous asymptomatic CMV infection in the whole HC group was 
considered unlikely to influence the comparability with the other 
groups (CHB, resolved infection) owing to the high prevalence of 
CMV positivity in the general population (about 80% in Europe and 
the USA).20
Table 5 shows the comparisons, among individuals with CHB, 
subjects with resolved infection, and HC, of the frequencies of the 
three KIR and HLA variables (HLA- A- Bw4, HLA- C2, KIR2DL3) that 
were identified as the most relevant to predict CHB in the models 
shown in Tables 3 and 4. The gene group HLA- A- Bw4 identified by 
the predictive model as detrimental is significantly under- represented 
in the general population (HC, 6 of 60, 10%) compared to CHB (58%) 
(crude OR: CHB vs HC, 12.38, P<.001) (Table 5). Interestingly, if we 
also included in the group of 60 healthy controls the 60 subjects with 
CMV symptomatic infection enrolled in the previous study (HBV 
uninfected subjects),8 as representative of the general population 
as well, the frequency of HLA- A- Bw4 does not change (10 of 120, 
8.3%), again confirming the reported HLA- A- Bw4 frequency estimate 
in a bigger sample, markedly different from that of the CHB patients 
(Table 5).
Similar findings were reported for the other detrimental gene 
group, HLA- C2, under- represented in the general population (HC, 
60%) compared to CHB (84%) (crude OR: CHB vs HC, 3.56, P<.01). 
In contrast, no significant difference is reported in the KIR2DL3 fre-
quencies between CHB and HC (crude OR, 1.26, P=.60) (Table 5). 
Conversely, the comparison between subjects with resolved infection 
and HC shows no significant difference between the groups except for 
the protective KIR2DL3 gene that was more frequent in subjects with 
resolved infection (98%) than in HC (77%) with a significant OR (crude 
OR, 13.09, P<.01) (Table 5).
Finally, the subgroup of 13 CHB patients with concomitant HIV 
infection had a higher frequency of HLA- A- Bw4 (69%) compared to 
CHB with only HBV infection (58%) (Table 5). The differences between 
this subgroup of CHB (HIV co- infected) and subjects with resolved in-
fection (crude OR, 7.65; P<.01), and HC (crude OR, 20.25; P<.001) 
were more marked than those observed with CHB (All). These findings 
are not shown for HLA- C2 and KIR2DL3 (Table 5).
Variable Code Est. β SE Adj. OR (95%CI) P- value
HLA- A- Bw4 0: absent 1.88 0.63 6.52 (1.88, 22.61) <.05
1: present
HLA- C2 0: absent 2.10 0.93 8.17 (1.33, 50.26) <.05
1: present
KIR2DL3 0: absent −3.19 1.34 0.04 (0, 0.57) <.01
1: present
Sex and age did not enter into the final model after the stepwise procedure. CHB, chronic hepatitis B; 
CI, confidence interval; Adj. OR, adjusted odds ratio; SE, standard error. The stepwise procedure has 
been carried out on a training set comprising randomly selected subjects. The training set dimension is 
75% of the overall sample dimension (with Ntrain=0.75*(44+57)=76).
TABLE  3 Logistic regression model to 
predict the effect of KIR and HLA alleles on 
the persistence of HBV infection (CHB)
TABLE  4 Predictive model for persistence of HBV infection 
(CHB)
Relative variable importancea
1. HLA- A- Bw4 100.0%
2. KIR2DL3 16.6%
3. HLA- C2 0.00%
Sensitivity 50.0%
Specificity 90.9%
Positive predictive value 87.5%
Negative predictive value 58.8%
Balanced accuracyb 70.5%
Cross- validated accuracyc 70.0%
The data set was randomly split into a training and a test set (75/25 split, 
75% of data for training set, 25% for test set). The training set was used for 
stepwise selection and effect size estimation of most relevant genes. The 
test set was used to assess the sensitivity, specificity and other predictive 
accuracy measures.
aThe variable relative importance values of the predictive model used for 
classifying future patients. The values were normalized to scale of 0%–
100%. CHB, chronic hepatitis B.
bBalanced accuracy is obtained as (sensitivity+specificity)/2, which turns 
out to be a more accurate estimator when one of the classes (the minority 
class, subjects with resolved infection) is under- represented as regards the 
other class (subjects with CHB).28
cCross- validated accuracy was calculated by means of 10- fold cross- 
validation. See the Supporting Information for further details.
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4  | DISCUSSION
This genetic association study shows that the KIR2DL3 inhibitory 
receptor gene and the KIR ligand group HLA- A- Bw4, and HLA- C2 
alleles predict the outcome of HBV infection. Subjects possessing 
HLA- A- Bw4 or HLA- C2 alleles are more susceptible to develop CHB, 
while the presence of KIR2DL3 seems to confer protection.
To our knowledge, this is the first study to show that the KIR ligand 
group HLA- A- Bw4 can influence the immune control of HBV. This ef-
fect may be mediated by the activation of the inhibitory KIR3DL1,21 
although an association with HLA- B- Bw4 alleles,5 that bind the same 
KIR gene, was not reported in this study. This may imply different 
binding affinity and consequently inhibitory ability between the HLA- 
A- Bw4 and HLA- B- Bw4 alleles. Furthermore, KIR3DL1 is among the 
most polymorphic of the KIR loci, and KIR3DL1 alleles show high vari-
ability in the level of their expression on cell surfaces, with functional 
repercussions.22
The results of the main analysis comparing CHB to subjects 
with resolved infection showed that the frequency of HLA- A- Bw4 
in CHB is about three times higher than in subjects with resolved 
infection (58% vs 23%), and this suggests a detrimental role of this 
ligand group. This possibility seems to be confirmed by the obser-
vation that in the general population the frequency of HLA- A- Bw4 
is much lower (10%) than in CHB (58%; OR, 12.38; P<.001) (Table 
5). This may be the result of a pathogen selective pressure leading 
to a decreased frequency of this detrimental ligand group in the 
general population. Indeed, the general population seems to be rel-
atively resistant to HBV, as less than 10% of subjects develop CHB 
after HBV infection. This percentage is very close to the frequency 
of the HLA- A- Bw4 in the general population (HC, 10%), and this 
gene was precisely the one identified by our stepwise analysis as the 
most important to predict the persistence of the infection (Table 4). 
A descriptive subgroup analysis was carried out comparing only the 
CHB patients co- infected with HIV (22.8%) with subjects with re-
solved infection and HC. This analysis showed that in the CHB/HIV 
co- infected group, the frequency of the HLA- A- Bw4 ligand was even 
higher (69%) than in the entire CHB group (58%), with a remarkably 
different OR compared to resolved infection (crude OR=7.65; P<.01) 
and HC (OR=20.25; P<.001) (Table 5). Despite the small sample size 
of this subgroup that limits the reliability of the analysis, these find-
ings may suggest that in a condition of immune suppression, NK cells 
may play a major role in the control of HBV infection. Further studies 
are needed to confirm these data, because the small sample size of 
this subgroup hampered the possibility to correlate the outcome to 
the CD4 T- cell count. However, for CMV infection, it was shown that 
in patients who had undergone bone marrow, HSCT or solid organ 
transplantation, specific KIR genes are associated with a low rate of 
CMV reactivation, suggesting that NK cells likely play a major role 
during immune suppression.
Also HLA- C2 alleles were more frequent in CHB (84%) than in sub-
jects with resolved infection (70%) and in healthy controls (60%). Even 
in this case, a linear increase from healthy controls to CHB was re-
ported, suggesting a possible pathogen selective pressure. The differ-
ence in the frequencies of HLA- C2 between the groups is less marked 
than HLA- A- Bw4, and accordingly, the relative predictive importance 
of this variable shown by the cross- validated model is lower than HLA- 
A- Bw4 (Table 4).
The KIR2DL3 gene is present in almost all the subjects who re-
solved the infection (98%), while less frequent in CHB (81%) and 
in healthy controls (77%). This difference may explain the different 
behaviour of the subjects after the infection, with higher chance of 
resolving the infection in subjects possessing this protective gene 
TABLE  5 Frequencies of KIR2DL3, HLA- C2 and HLA- A- Bw4 among individuals with CHB, subjects with resolved infection and healthy 
controls
Genetic factor
Frequency 
CHB 
N (%)
Frequency 
resolved 
N (%)
Frequency 
HC 
N (%)
Crude OR 
(CHB vs 
resolved) P
Crude OR 
(CHB vs HC) P
Crude OR 
(resolved vs HC) P
HLA- A- Bw4
All 33/57 (58) 10/44 (23) 6/60 (10) 4.67 <.001 12.38 <.001 2.56 .07
HIV 
co- infected
9/13 (69) 7.65 <.01 20.25 <.001
HLA- C2
All 48/57 (84) 31/44 (70) 36/60 (60) 2.24 .09 3.56 <.01 1.59 .27
HIV 
co- infected
11/13 (85) 2.31 .30 3.67 .09
KIR2DL3
All 46/57 (81) 43/44 (98) 46/60 (77) 0.10 <.05 1.26 .59 13.09 <.01
HIV 
co- infected
10/13 (77) 0.08 <.01 1.01 .98
CHB, Chronic hepatitis B; resolved, subjects with resolved HBV infection; HC, healthy controls; OR, odds ratio; All: all 57 patients with chronic hepatitis B; 
HIV co- infected: a subgroup of 13 patients with HBV/HIV co- infection out of the 57 CHB patients. The HIV co- infected subgroup was compared to the 
resolved infection and the HC groups.
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(resolved infection group). The mechanism responsible for the pro-
tective role of KIR2DL3 is unclear, as this gene codes for an inhibitory 
receptor. Khakoo et al. showed that in HCV infection, the presence 
of the KIR2DL3- HLA- C1 interaction is associated with resolved in-
fection.12 KIR2DL3 binds HLA- C1 with a weaker affinity compared 
to KIR2DL2. Therefore, the authors hypothesized that this weaker 
inhibitory receptor- ligand interaction (KIR2DL3- HLA- C1) would be 
protective, because it should be more easily overridden by activat-
ing signals than a stronger inhibitory interaction such as KIR2DL2- 
HLA- C1.12 In the multiple logistic regression analysis, we did not 
analyse the combined KIR- HLA interactions with this set of data as 
adding interaction terms to the full model would have led to strong 
over- parameterization (with respect to the limited sample size), and 
poor statistical inference. However, the descriptive univariate anal-
ysis (Table 2) showed that the KIR2DL3- HLA- C1 combination was 
indeed more frequent in CHB than in resolved infection, despite the 
loss of significance of the HLA- C1 in the multiple logistic regression 
analysis, supporting the role of this receptor- ligand association. Our 
findings are consistent with three other studies, one from Brazil,14 
one from China15 and one from Turkey,16 which reported a protec-
tive effect of KIR2DL3 or the interaction between KIR2DL3 and 
HLA- C1, suggesting a possible generalizability of the protective role 
of KIR2DL3 to different populations.
Genetic diversity of the KIR/HLA system was recently shown to be 
associated with the susceptibility of hepatitis C virus- related diseases, 
such as hepatocarcinoma (HCC) or lymphoproliferative diseases, con-
firming the role of KIR/HLA interaction in the outcome of viral hepatic 
infections.23
As already mentioned, HLA- A- Bw4, HLA- C2 and KIR2DL3 were 
identified as the best variables to predict the outcome of HBV in-
fection by the stepwise covariate selection. According to the model, 
patients with at least one of the two detrimental ligand groups 
(HLA- A- Bw4 or HLA- C2) are going to be classified as at risk of de-
veloping CHB, unless they do not possess the protective KIR2DL3 
gene (Table S1 in Supporting Information). Furthermore, if both 
the detrimental genes are present, the subject has a high chance 
of developing CHB even with the presence of the protective gene 
KIR2DL3 (Table S1 in Supporting Information). The performance 
of this model was low for sensitivity (50%), but high for specificity 
(90.1%) and positive predictive value (87.5%). This means that using 
the three predicting variables, a subject classified by the model as 
at risk of developing CHB has a chance of about 88% of actually 
developing a chronic disease. This model is consistent with the as-
sumption that NK cell activity is influenced by a balance between 
signal with variable activating and inhibitory activity. Therefore, this 
approach seems to be particularly suitable for facing the complexity 
of activating vs inhibitory KIR (and their HLA ligands) that deter-
mine NK cell function, as it is not based on the analysis of a single 
gene, but a combination of genes variably influencing the outcome 
(Figure 1).
A limitation of this analysis is the relatively small sample size. This 
may reduce the statistical power and limit the ability to identify some 
relevant association between KIR and HLA ligand groups with the 
outcome. On the other hand, the differences between the groups 
reported in this study are remarkable and highly statistically signif-
icant, strengthening the importance of this exploratory analysis. It 
is worth noting that the inflammatory infiltrate in the liver infected 
by HBV is particularly rich in NK cells (30–40% of total intrahepatic 
lymphocytes), and NK activity is high early in HBV infection and 
during the incubation time, suggesting that these cells are import-
ant in the pathogenesis of CHB.24-27 Although the ability of NK cells 
to contribute to control of HBV has been demonstrated in mouse 
models, their importance in human HBV- infected liver is still unclear 
(innocent bystanders or potent players?).2 Considering the complex-
ity of the immune system, the highly significant results reported here 
analysing only a single family of NK receptors and their HLA ligands 
suggest that NK probably plays an active role in HBV control.
Another important limitation is that an external validation of these 
data is needed to assess the generalizability of our findings to other 
populations, as we studied subjects of the same geographic area and 
ethnicity. Studies are ongoing to assess if spontaneous reactivation of 
HBV occurring in elderly patients with resolved or occult infection may 
be associated to different KIR/HLA genetic differences.
In conclusion, we used a genetic approach to provide evidence for 
a protective effect of the KIR2DL3 gene and a detrimental effect of 
the HLA- A- Bw4 and HLA- C2 alleles on the outcome of primary HBV 
infection, suggesting that KIR and HLA polymorphisms play a primary 
role in the control of the infection. Genetic differences are present be-
tween subjects with different abilities to respond to primary HBV in-
fection, suggesting that specific KIR and HLA gene segregations were 
likely the result of a pathogen selective pressure.
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